FTC Targets Disclosures, “Up To” And “Doctor-Recommended” Claims
This article was originally published in The Rose Sheet
Executive Summary
“A lot of research casts doubt on the effectiveness of disclosures,” says FTC official Richard Cleland. FTC will also zero in on “up to,” “doctor-recommended” and business-to-business claims, he notes.
You may also be interested in...
FTC Brings Dot-Com Disclosure Guide To Social Media, Mobile Era
Revised online advertising disclosure guidelines detail FTC’s expectations for how advertisers should craft disclosures in the world of social media and mobile devices.
J&J Consumer Sales Slip Even As Recalled Brands, Seasonal Items Reach Stores
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.
Ensuring Leading Position For GSK Consumer Products Touted In Management Shift
GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.